Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Ibrutinib in WaldenstrÃ¶m's Macroglobulinemia

June 30th 2015

B-Cell Receptor Inhibitor Response Criteria in CLL

June 30th 2015

Emerging Strategies in CLL and Follicular Lymphoma

June 30th 2015

Ibrutinib-Associated Adverse Events

June 30th 2015

Ibrutinib Monotherapy and Combinations in CLL

June 30th 2015

Preventing Infusion Reactions With CD20 Antibodies in CLL

June 30th 2015

Role of B-Cell Receptor Signaling Inhibitors in CLL

June 30th 2015

Changing Treatment Landscape in CLL

June 30th 2015

Dr. Diefenbach on Ipilimumab/Brentuximab Vedotin in Patients With RR Hodgkin Lymphoma

June 30th 2015

Catherine M. Diefenbach, MD, assistant professor, Department of Medicine, NYU Langone Medical Center, discusses a phase I study with an expansion cohort examining the combination of ipilimumab and brentuximab vedotin for the treatment of patients with relapsed/refractory Hodgkin lymphoma.

Celgene, Juno Ink $1 Billion Immunotherapy Deal

June 30th 2015

Celgene has entered into a 10-year collaboration with the cellular immunotherapy company Juno Therapeutics, which includes an initial $1 billion payment.

Krebs Cycle: A Role for Metabolic Enzymes in Acute Myeloid Leukemia

June 29th 2015

One promising avenue of exploration of biomarkers in AML is the Krebs cycle, where inhibiting a key metabolic enzyme has proved beneficial in early clinical studies.

Novel Combination Strategies Explored in Two Phase III NHL Studies

June 26th 2015

John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.

Treatment Options in the Relapsed/Refractory Setting

June 26th 2015

Is It Okay to Stop Therapy in CML Patients?

June 26th 2015

The Importance of Frequent Monitoring in CML

June 26th 2015

Nilotinib and Dasatinib Versus Imatinib in CML

June 26th 2015

Changing Treatment Landscape in CML

June 26th 2015

Initial Phase III Data Positive for CPX-351 in High-Risk AML

June 25th 2015

Treatment with CPX-351 led to a relative improvement in induction response of over 40% compared with conventional 7+3 cytarabine/daunorubicin in patients with secondary acute myeloid leukemia.

Future Immunotherapies for Hematologic Malignancies

June 24th 2015

PD-1 Inhibition in Hodgkin's Lymphoma

June 24th 2015